Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models

Nature Communications

Volumn 8, Issue , 2017, Pages

  Hwang, In Young ^a,b   Koh, Elvin ^a,b   Wong, Adison ^a,b   March, John C ^c   Bentley, William E ^d   Lee, Yung Seng ^a,b   Chang, Matthew Wook ^a,b  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Department of Biological and Environmental Engineering   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE RACEMASE; PROBIOTIC AGENT;

BACTERIUM; BIOFILM; ENZYME ACTIVITY; GENETIC ENGINEERING; INFECTIVITY; NEMATODE; PATHOGEN; PROBIOTICS; RODENT; VIRULENCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CAENORHABDITIS ELEGANS; CONTROLLED STUDY; DRUG EFFICACY; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; FEMALE; GENETIC ENGINEERING; IN VIVO STUDY; INFECTION PREVENTION; INTESTINE INFECTION; MOUSE; NONHUMAN; PSEUDOMONAS INFECTION; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; GASTROENTERITIS; GENETICS; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIOLOGY; PATHOGENICITY; PROCEDURES; PSEUDOMONAS AERUGINOSA; TRANSGENIC MICROORGANISM; VIRULENCE;

ANIMALIA; BACTERIA (MICROORGANISMS); CAENORHABDITIS ELEGANS; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; MUS; PSEUDOMONAS AERUGINOSA;

ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; GASTROENTERITIS; GENETIC ENGINEERING; MICE; MICE, INBRED ICR; MICROORGANISMS, GENETICALLY-MODIFIED; PROBIOTICS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; VIRULENCE;

EID: 85017396256     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15028     Document Type: Article

References (48)

1. Renwick, M. J., Brogan, D. M., Mossialos, E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. J. Antibiotics 69, 73-88 (2015).
2. Ukena, S. N., et al. Probiotic Escherichia coli Nissle 1917 inhibits leaky gut by enhancing mucosal integrity. PLoS ONE 2, e1308-e1308 (2007).
3. Schultz, M. Clinical use of E. coli Nissle 1917 in inflammatory bowel disease. Inflamm. Bowel Dis. 14, 1012-1018 (2008).
4. Westendorf, A. M., et al. Intestinal immunity of Escherichia coli NISSLE 1917: A safe carrier for therapeutic molecules. FEMS Immunol. Med. Microbiol. 43, 373-384 (2005).
5. Leatham, M. P., et al. Precolonized human commensal Escherichia coli strains serve as a barrier to E. coli O157:H7 growth in the streptomycin-treated mouse intestine. Infect. Immunity 77, 2876-2886 (2009).
6. Hancock, V., Dahl, M., Klemm, P. Probiotic Escherichia coli strain Nissle 1917 outcompetes intestinal pathogens during biofilm formation. J. Med. Microbiol. 59, 392-399 (2010).
7. Goh, Y.-L., He, H., March, J. C. Engineering commensal bacteria for prophylaxis against infection. Curr. Opin. Biotechnol. 23, 924-930 (2012).
8. Duval, M., et al. Enhanced neutralization of HIV by antibodies displayed on the S-layer of Caulobacter crescentus. Antimicrob. Agents Chemother. 55, 5547-5552 (2011).
9. Farr, C., et al. Development of an HIV-1 microbicide based on: Blocking infection by high-density display of virus entry inhibitors. PLoS ONE 8, e65965 (2013).
10. Volzing, K., Borrero, J., Sadowsky, M. J., Kaznessis, Y. N. Antimicrobial peptides targeting Gram-negative pathogens, produced and delivered by lactic acid bacteria. ACS Synth. Biol. 2, 643-650 (2013).
11. Gupta, S., Bram, E. E., Weiss, R. Genetically programmable pathogen sense and destroy. ACS Synth. Biol. 2, 715-723 (2013).
12. Lu, T. K., Collins, J. J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc. Natl Acad. Sci. 106, 4629-4634 (2009).
13. Duan, F. F., Liu, J. H., March, J. C. Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes. Diabetes 64, 1794-1803 db140635-db140635 (2015).
14. Duan, F., March, J. C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model. Proc. Natl Acad. Sci. USA 107, 11260-11264 (2010).
15. Din, M. O., et al. Synchronized cycles of bacterial lysis for in vivo delivery. Nature 536, 81-85 (2016).
16. St Jean, A. T., Swofford, C. A., Panteli, J. T., Brentzel, Z. J., Forbes, N. S. Bacterial delivery of Staphylococcus aureus alpha-hemolysin causes regression and necrosis in murine tumors. Mol. Ther. 22, 1266-1274 (2014).
17. Smith, E. E., et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. 103, 8487-8492 (2006).
18. Markou, P., Apidianakis, Y. Pathogenesis of intestinal Pseudomonas aeruginosa infection in patients with cancer. Front. Cell. Infect. Microbiol. 3, 115 (2013).
19. Rolston, K. V., Bodey, G. P. Pseudomonas aeruginosa infection in cancer patients. Cancer Investig. 10, 43-59 (1992).
20. Alverdy, J., et al. Gut-derived sepsis occurs when the right pathogen with the right virulence genes meets the right host: Evidence for in vivo virulence expression in Pseudomonas aeruginosa. Ann. Surg. 232, 480-489 (2000).
21. Watanabe, R., et al. Efficacy of bacteriophage therapy against gut-derived sepsis caused by Pseudomonas aeruginosa in mice. Antimicrob. Agents Chemother. 51, 446-452 (2007).
22. Marshall, J. C., Christou, N. V., Meakins, J. L. The gastrointestinal tract. The 'undrained abscess' of multiple organ failure. Ann. Surg. 218, 111-119 (1993).
23. de Jonge, E., et al. Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: A randomised controlled trial. Lancet 362, 1011-1016 (2003).
24. Zaborina, O., et al. Identification of multi-drug resistant Pseudomonas aeruginosa clinical isolates that are highly disruptive to the intestinal epithelial barrier. Ann. Clin. Microbiol. Antimicrob. 5, 14-14 (2006).
25. Okuda, J., et al. Translocation of Pseudomonas aeruginosa from the intestinal tract is mediated by the binding of ExoS to an Na, K-ATPase regulator, FXYD3. Infect. Immunity 78, 4511-4522 (2010).
26. Koh, A. Y., Priebe, G. P., Pier, G. B. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect. Immunity 73, 2262-2272 (2005).
27. Chuang, C.-H., et al. Shanghai fever: A distinct Pseudomonas aeruginosa enteric disease. Gut 63, 736-743 (2014).
28. Rowe, M. I., Reblock, K. K., Kurkchubasche, A. G., Healey, P. J. Necrotizing enterocolitis in the extremely low birth weight infant. J. Pediatr. Surg. 29, 987-990 discussion 990-981 (1994).
29. Saeidi, N., et al. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen. Mol. Syst. Biol. 7, 521-521 (2011).
30. Itoh, Y., et al. Depolymerization of b-1, 6-N-Acetyl-D-Glucosamine disrupts the integrity of diverse bacterial biofilms. J. Bacteriol. 187, 382-387 (2005).
31. Walsh, C. T. Enzymes in the D-alanine branch of bacterial cell wall peptidoglycan assembly. J. Biol. Chem. 264, 2393-2396 (1989).
32. Wild, J., Hennig, J., Lobocka, M., Walczak, W., Klopotowski, T. Identification of the dadX gene coding for the predominant isozyme of alanine racemase in Escherichia coli K12. Mol. Gen. Genet. 198, 315-322 (1985).
33. Datsenko, K. A., Wanner, B. L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl Acad. Sci. USA 97, 6640-6645 (2000).
34. Lee, T., et al. BglBrick vectors and datasheets: A synthetic biology platform for gene expression. J. Biol. Eng. 5, 12-12 (2011).
35. Scott, M., Gunderson, C. W., Mateescu, E. M., Zhang, Z., Hwa, T. Interdependence of cell growth and gene expression: Origins and consequences. Science 330, 1099-1102 (2010).
36. Wessely, F., et al. Optimal regulatory strategies for metabolic pathways in Escherichia coli depending on protein costs. Mol. Syst. Biol. 7, 515 (2011).
37. Bentley, W. E., Mirjalili, N., Andersen, D. C., Davis, R. H., Kompala, D. S. Plasmid-encoded protein: The principal factor in the 'metabolic burden' associated with recombinant bacteria. Biotechnol. Bioeng. 35, 668-681 (1990).
38. Tan, M. W., Mahajan-Miklos, S., Ausubel, F. M. Killing of Caenorhabditis elegans by Pseudomonas aeruginosa used to model mammalian bacterial pathogenesis. Proc. Natl Acad. Sci. USA 96, 715-720 (1999).
39. Terrell, J. L., et al. Nano-guided cell networks as conveyors of molecular communication. Nat. Commun. 6, 8500 (2015).
40. Parret, A., De Mot, R., Pavel, D. Novel bacteriocins with predicted tRNase and pore-forming activities in Pseudomonas aeruginosa PAO1. Mol. Microbiol. 35, 1995-1998 (2000).
41. Rasouliha, B. H., Ling, H., Ho, C. L., Chang, M. W. A predicted immunity protein confers resistance to Pyocin S5 in a sensitive strain of Pseudomonas aeruginosa. ChemBioChem 14, 2444-2446 (2013).
42. Maltby, R., Leatham-Jensen, M. P., Gibson, T., Cohen, P. S., Conway, T. Nutritional basis for colonization resistance by human commensal Escherichia coli Strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine. PLoS ONE 8, e53957-e53957 (2013).
43. Ling, H., Saeidi, N., Rasouliha, B. H., Chang, M. W. A predicted S-type pyocin shows a bactericidal activity against clinical Pseudomonas aeruginosa isolates through membrane damage. FEBS Lett. 584, 3354-3358 (2010).
44. Canton, B., Labno, A., Endy, D. Refinement and standardization of synthetic biological parts and devices. Nat. Biotechnol. 26, 787-793 (2008).
45. Ceri, H., Olson, M. E., Stremick, C. The calgary biofilm device: New technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37, 1771-1776 (1999).
46. Moskowitz, S. M., Foster, J. M., Emerson, J., Burns, J. L., Icrobiol, J. C. L. I. N. M. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42, 1915-1922 (2004).
47. Davies, D. G., et al. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280, 295-298 (1998).
48. Powell, J. R., Ausubel, F. M. Models of Caenorhabditis elegans infection by bacterial and fungal pathogens. Methods Mol. Biol. 415, 403-427 (2008).